Shanxi Zhendong Pharmaceutical Co.,Ltd

XSEC:300158 Stock Report

Market Cap: CN¥4.5b

Shanxi Zhendong PharmaceuticalLtd Past Earnings Performance

Past criteria checks 0/6

Shanxi Zhendong PharmaceuticalLtd's earnings have been declining at an average annual rate of -5.3%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been declining at an average rate of 7.3% per year.

Key information

-5.3%

Earnings growth rate

-5.3%

EPS growth rate

Pharmaceuticals Industry Growth10.9%
Revenue growth rate-7.3%
Return on equity-0.1%
Net Margin-0.1%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Shanxi Zhendong PharmaceuticalLtd makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

XSEC:300158 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 243,112-31,473200
30 Jun 243,200-281,547204
31 Mar 243,457-201,638181
31 Dec 233,626-441,741191
30 Sep 233,713-771,773191
30 Jun 233,936-611,850177
31 Mar 233,791-611,825175
01 Jan 233,729-511,793178
30 Sep 223,8412,3191,935194
30 Jun 224,1732,4212,126222
31 Mar 224,6892,5292,415223
01 Jan 225,0942,6172,653219
30 Sep 215,5283782,782161
30 Jun 215,5203652,864151
31 Mar 215,1962992,740149
31 Dec 204,8482622,576136
30 Sep 204,6532082,594177
30 Jun 204,4011542,435172
31 Mar 204,4451522,482163
31 Dec 194,3991432,492145
30 Sep 194,155-672,430168
30 Jun 193,772-1332,305134
31 Mar 193,546-1472,132128
31 Dec 183,420-1472,078123
30 Sep 183,7461202,116122
30 Jun 183,7382331,956151
31 Mar 183,7862951,828131
31 Dec 173,7323021,632118
30 Sep 173,7023431,39844
30 Jun 173,7773301,3270
31 Mar 173,5042431,2600
31 Dec 163,2832031,1820
30 Sep 162,6881171,0370
30 Jun 162,383679330
31 Mar 162,323679080
31 Dec 152,262659200
30 Sep 152,165518090
30 Jun 152,199438320
31 Mar 152,010407940
31 Dec 141,919427650
30 Sep 141,673567600
30 Jun 141,711707250
31 Mar 141,695687030
31 Dec 131,658746950

Quality Earnings: 300158 is currently unprofitable.

Growing Profit Margin: 300158 is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 300158 is unprofitable, and losses have increased over the past 5 years at a rate of 5.3% per year.

Accelerating Growth: Unable to compare 300158's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 300158 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-2.5%).

Return on Equity

High ROE: 300158 has a negative Return on Equity (-0.14%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 11:05
End of Day Share Price 2024/12/26 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Shanxi Zhendong Pharmaceutical Co.,Ltd is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Wenchao JiaoPing An Securities Co. Ltd.
Yin YePing An Securities Co. Ltd.
Wen Qing WeiShenwan Hongyuan Securities